CN111012736A - Application of sterile spray dressing for blocking novel coronavirus 2019-nCov - Google Patents
Application of sterile spray dressing for blocking novel coronavirus 2019-nCov Download PDFInfo
- Publication number
- CN111012736A CN111012736A CN202010086854.1A CN202010086854A CN111012736A CN 111012736 A CN111012736 A CN 111012736A CN 202010086854 A CN202010086854 A CN 202010086854A CN 111012736 A CN111012736 A CN 111012736A
- Authority
- CN
- China
- Prior art keywords
- spray dressing
- lht
- sterile spray
- bioactive peptide
- sterile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Abstract
The invention relates to application of an aseptic spray dressing, in particular to application of an aseptic spray dressing for blocking a novel coronavirus 2019-nCov. The main component of the sterile spray dressing is bioactive peptide LHT which is sprayed into the nasal cavity or the oral cavity to form a protective layer, when viruses contact the protective layer of the nasal cavity or the oral cavity, the bioactive peptide LHT is rapidly combined with capsid M protein of the viruses, so that the bioactive peptide LHT is blocked outside the body before contacting human cells. On the other hand, after the main component of the sterile spray dressing, namely the bioactive peptide LHT, is sprayed into the nasal cavity or the oral cavity, the bioactive peptide LHT can also be combined with the exposed parts of angiotensin converting enzyme ACE and ACE2 protease on the epidermal cell membrane of the human body, so that the approach of the novel coronavirus to invade cells is blocked.
Description
Technical Field
The invention relates to application of an aseptic spray dressing, in particular to application of an aseptic spray dressing for blocking a novel coronavirus 2019-nCov.
Background
2019 novel coronavirus (2019-nCoV), and named by world health organization in 12 months 1 and 2020. Coronaviruses belong to the phylogenetic group of Coronaviridae (Coronaviridae) coronaviruses (Coronavirus). Viruses of the genus coronavirus are positive-stranded single-stranded RNA viruses with an envelope structure that has three proteins: spike glycoprotein (S), small Envelope glycoprotein (E), and Membrane glycoprotein (M). The S protein recognizes and combines with a host cell surface receptor and mediates fusion of a virus envelope and a cell membrane; the M protein is involved in the formation and budding of the virus envelope. Research shows that the novel coronavirus is capable of recognizing angiotensin converting enzyme ACE and ACE2 protease on cell membranes of bronchial epithelial cells and alveolar cells of human bodies through the S protein of the novel coronavirus to be combined and invaded into the human bodies, so that pneumonia is infected. 2019 the novel coronavirus is the 7 th coronavirus which is known to infect human, and the remaining 6 are HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV, respectively.
After a person is infected with 2019 novel coronavirus, acute infectious pneumonia can be caused, and the initial symptoms of the patient are fever, weakness and dry cough, and severe manifestations such as dyspnea gradually appear. The prognosis is good in most patients and acute respiratory distress syndrome or septic shock may occur in some severe cases and even death. 2019 the pneumonia caused by the novel coronavirus is high in infectivity. Based on the current epidemiological investigation, the latent period is 1-14 days, the latent period of a few infected persons exceeds 14 days, the latent period is infectious, and asymptomatic infected persons can also become the source of infection. The 2019 novel coronavirus transmission routes which can be determined at present are mainly direct transmission, aerosol transmission and contact transmission. Direct transmission refers to infection caused by sneezing, coughing, speaking droplets and direct inhalation of exhaled air in close proximity; aerosol transmission refers to the mixing of droplets in the air to form an aerosol which causes infection after inhalation; contact transmission refers to the condition that droplets are deposited on the surface of an article and contact with mucous membranes such as oral cavity, nasal cavity, eyes and the like after contacting with contaminated hands, so that infection is caused. However, currently, there are very limited medical products and drugs that can safely and effectively block the infection of the novel coronavirus.
Disclosure of Invention
In order to make up for the defects, the invention aims to provide the application of the sterile spray dressing for blocking the novel coronavirus 2019-nCov. The sterile spray dressing is sprayed into the nasal cavity or the oral cavity to form a protective layer, which can prevent the invasion of external substances such as viruses, and has no toxic or side effect, safety and reliability.
The invention discloses an application of a sterile spray dressing for blocking a novel coronavirus 2019-nCov, and the technical scheme adopted for solving the technical problem comprises the following contents:
the aseptic spray dressing contains bioactive peptide LHT and auxiliary materials, wherein the addition amount of the bioactive peptide LHT is 0.1-0.5%, the auxiliary materials contain 0.1-1% of thickening agent, 0.01-0.5% of preservative, 0.01-0.2% of citric acid, 0.3-0.9% of sodium chloride, 0.1-1.5% of disodium hydrogen phosphate, 0.01-0.06% of disodium ethylene diamine tetraacetate, and the volume of purified water is up to 100%.
The thickener is preferably one of hydroxyethyl cellulose and sodium carboxymethyl cellulose.
The antiseptic is preferably one or more of methyl hydroxybenzoate, sodium hydroxybenzoate and ethylparaben.
The application of the sterile spray dressing is characterized in that the bioactive peptide LHT contained in the sterile spray dressing is derived from a mixture of enzymatic hydrolysis of bioactive peptide of schizochytrium limacinum and donkey serum protein.
The bioactive peptide of the microalgae schizochytrium sourced from the ocean is obtained by extracting DHA (docosahexaenoic acid) from algal dregs obtained after fermenting the microalgae schizochytrium sourced from the ocean, degrading by protease, separating and purifying, and can be combined with capsid M protein of coronavirus, so that the bioactive peptide is blocked outside the body before contacting human cells to prevent the bioactive peptide from entering the human body.
The microalgae schizochytrium limacinum is a new food raw material approved by the Ministry of health of the people's republic of China (No. 3 in 2010), adopts the international leading bioinformatics technology, and is used for target positioning and separation of active peptide LHT (LHT), and is a main raw material for producing sterile spray dressing, and the safety, the non-toxicity and the reliability of the microalgae schizochytrium limacinum are proved by the national authority.
The donkey serum albumin has been proved by research that peptides obtained by enzymolysis of donkey serum proteins have an inhibitory effect on angiotensin converting enzyme and can be combined with exposed external parts of angiotensin converting enzyme ACE and ACE2 protease on human epidermal cell membranes, so that the approach of novel coronavirus invading cells is blocked.
In addition, the ethylene diamine tetraacetic acid disodium in the sterile spray dressing has research to show that the aseptic spray dressing also has the effect of blocking coronavirus.
The invention also provides application of the sterile spray dressing for blocking the novel coronavirus 2019-nCov.
The application of the sterile spray dressing is characterized in that the amino acids contained in the bioactive peptide LHT contained in the sterile spray dressing are alanine (Ala), arginine (Arg), aspartic acid (Asp), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), asparagine (Asn) and cysteine (Cys).
The application of the sterile spray dressing is characterized in that the molecular formula of bioactive peptide contained in the bioactive peptide LHT contained in the sterile spray dressing is C43H76N10O18，C29H47N6O9，C33H60N7O9，C28H49N6O8S。
The sterile spray dressing is applied to II and III medical appliance products.
The sterile spray dressing is used for the oral cavity or the nasal cavity.
The bioactive peptide LHT of the aseptic spray dressing is derived from a mixture of the enzymatic hydrolysis bioactive peptide of the marine microalgae schizochytrium limacinum and the enzymatic hydrolysis of donkey serum protein, has good synergistic effect, and can block viruses from invading human bodies from two aspects:
on one hand: the bioactive peptide LHT is combined with the virus capsid protein Mpro to play a barrier role to the human body:
the sterile spray dressing containing the bioactive peptide LHT is sprayed into the nasal cavity or the oral cavity to form a protective layer, and when viruses contact the protective layer of the nasal cavity or the oral cavity, the bioactive peptide LHT is rapidly combined with capsid M protein of the viruses, so that the bioactive peptide LHT is blocked outside the body before contacting human cells. The protective layer acts as a barrier to viruses, blocking their entry into the body.
On the other hand: the bioactive peptide LHT can compete with the virus capsid protein to combine with the protein outside the human epidermal cell membrane to block the approach of virus invading the human cells, and plays a barrier role to the human body:
the sterile spray dressing containing bioactive peptide LHT can be sprayed into nasal cavity or oral cavity, and can also be combined with exposed external parts of angiotensin converting enzyme ACE and ACE2 protease on human epidermal cell membrane, so that the approach of novel coronavirus invading cell is blocked. Namely, a barrier is formed by the sterile spray dressing and the outside of human cells together, and the novel coronavirus is blocked from invading the human body.
Detailed Description
In order to make the technical solution of the present invention more clearly known to those skilled in the art, the following combination tool
The embodiments of the present invention will be described in detail.
Example 1
0.18 percent of bioactive peptide LHT, 0.3 percent of sodium carboxymethylcellulose, 0.02 percent of sodium methyl hydroxybenzoate, 0.12 percent of citric acid, 0.48 percent of sodium chloride, 1.4 percent of disodium hydrogen phosphate, 0.05 percent of ethylene diamine tetraacetic acid and purified water with constant volume of 100 percent.
Example 2
0.18 percent of bioactive peptide LHT, 0.3 percent of sodium carboxymethylcellulose, 0.02 percent of sodium methyl hydroxybenzoate, 0.12 percent of citric acid, 0.48 percent of sodium chloride, 0.14 percent of disodium hydrogen phosphate, 0.05 percent of ethylene diamine tetraacetic acid and purified water with constant volume of 100 percent.
Example 3
0.18 percent of bioactive peptide LHT, 0.3 percent of hydroxyethyl cellulose, 0.02 percent of sodium methyl hydroxybenzoate, 0.12 percent of citric acid, 0.48 percent of sodium chloride, 0.14 percent of disodium hydrogen phosphate, 0.05 percent of disodium ethylene diamine tetraacetate and purified water with constant volume of 100 percent.
Example 4 sterile spray dressing experience survey
30 volunteers were recruited, and each volunteer sprayed the sterile spray dressing prepared in example 1, example 2 and example 3 to the oral cavity and the nasal cavity respectively for sensory evaluation, and the specific experience effects were as follows: 30 volunteers of the sterile spray dressings prepared in examples 1 to 3 all felt a slightly salty taste, wherein 1 volunteer felt that the sterile spray dressings of examples 1 and 2 had sensitive and irritating manifestations when sprayed into the nasal cavity, and 30 volunteers of the sterile spray dressing of example 3 had no sensitive and irritating manifestations when sprayed into the oral cavity and the nasal cavity.
The embodiment described above is not all embodiments of the present invention, and the detailed description of the embodiment is not intended to limit the present invention, but only shows selected embodiments of the present invention. Those skilled in the art can now appreciate that many changes can be made to the embodiments described above.
Claims (10)
1. The application of the sterile spray dressing for blocking the novel coronavirus 2019-nCov is characterized in that the sterile spray dressing contains bioactive peptide LHT and auxiliary materials, wherein the addition amount of the bioactive peptide LHT is 0.1-0.5%, the auxiliary materials contain 0.1-1% of a thickening agent, 0.01-0.5% of a preservative, 0.01-0.2% of citric acid, 0.3-0.9% of sodium chloride, 0.1-1.5% of disodium hydrogen phosphate, 0.01-0.06% of disodium ethylene diamine tetraacetate and a proper amount of purified water, the thickening agent is preferably one of hydroxyethyl cellulose and sodium carboxymethyl cellulose, and the preservative is preferably one or more of methyl hydroxybenzoate, sodium hydroxybenzoate and ethylparaben.
2. The use of the sterile spray dressing according to claim 1, wherein the bioactive peptide LHT contained in the sterile spray dressing is derived from a mixture of enzymatic hydrolysis active peptide of schizochytrium limacinum and donkey serum protein.
3. The use of the sterile spray dressing according to claims 1-2, wherein the bioactive peptide LHT contained in the sterile spray dressing contains amino acids such as alanine (Ala), arginine (Arg), aspartic acid (Asp), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), asparagine (Asn), cysteine (Cys).
4. The use of sterile spray dressing according to claims 1-3, wherein the bioactive peptide LHT contained in the sterile spray dressing has a bioactive peptide formula C43H76N10O18，C29H47N6O9，C33H60N7O9，C28H49N6O8S。
5. The use of the sterile spray dressing of claims 1-4, wherein the sterile spray dressing is used in a class II, III medical device product.
6. The use of the sterile spray dressing according to claims 1-5, wherein the sterile spray dressing is for use in the oral or nasal cavity.
7. The use of the sterile spray dressing according to claims 1-6, wherein the main component of the sterile spray dressing is bioactive LHT which can also bind to viruses, inactivate the viruses and shield the viruses from the outside of the human body.
8. The use of the sterile spray dressing according to claim 7, wherein the main component of the sterile spray dressing is bioactive peptide LHT which forms a protective layer after being sprayed into the nasal cavity or the oral cavity, and when viruses contact the protective layer of the nasal cavity or the oral cavity, the bioactive peptide LHT is rapidly combined with capsid M protein of the viruses, so that the bioactive peptide LHT is blocked outside the human body before contacting human body cells.
9. The use of the sterile spray dressing according to claims 1-6, wherein the main component of the sterile spray dressing is bioactive peptide LHT which can compete with virus capsid protein to bind with protein outside human epidermal cell membrane, thereby blocking the way of virus invading human cells.
10. The use of the sterile spray dressing according to claim 9, wherein the main ingredient of the sterile spray dressing is bioactive peptide LHT which is sprayed into nasal cavity or oral cavity and can be combined with the exposed external parts of angiotensin converting enzyme ACE and ACE2 protease on human epidermal cell membrane, so that the path of new coronavirus invading cells is blocked.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010086854.1A CN111012736A (en) | 2020-02-11 | 2020-02-11 | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010086854.1A CN111012736A (en) | 2020-02-11 | 2020-02-11 | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111012736A true CN111012736A (en) | 2020-04-17 |
Family
ID=70203418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010086854.1A Pending CN111012736A (en) | 2020-02-11 | 2020-02-11 | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111012736A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111474350A (en) * | 2020-04-23 | 2020-07-31 | 中国林业科学研究院林业研究所 | Kit for detecting coronavirus S1 antigen and non-diagnosis-purpose detection method thereof |
| IT202100016037A1 (en) * | 2021-06-18 | 2021-09-18 | Antonio Bianchi | SPRAY FORMULATION FOR NASAL/ORAL USE WITH ACTIVITY AGAINST RESPIRATORY CORONAVIRUSES |
| WO2022084931A1 (en) * | 2020-10-23 | 2022-04-28 | Antonio Bianchi | Spray formulation for nasal/oral use with activity against respiratory coronaviruses and in particular the sars-cov-2 virus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110195449A1 (en) * | 2009-12-28 | 2011-08-11 | Martek Biosciences Corporation | Recombinant Thraustochytrids that Grow on Sucrose, and Compositions, Methods of Making, and Uses Thereof |
| CN105555290A (en) * | 2013-05-10 | 2016-05-04 | 莱顿大学学术医院以Lumc的名义运作 | Antimicrobial peptide |
| CN106755229A (en) * | 2016-11-24 | 2017-05-31 | 福州大学 | A kind of preparation method of schizochytrium limacinum algae cake protein Peptides |
| WO2017197542A1 (en) * | 2016-05-20 | 2017-11-23 | 浙江红雨医药用品有限公司 | Antibacterial dressing, and preparation method and use thereof |
-
2020
- 2020-02-11 CN CN202010086854.1A patent/CN111012736A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110195449A1 (en) * | 2009-12-28 | 2011-08-11 | Martek Biosciences Corporation | Recombinant Thraustochytrids that Grow on Sucrose, and Compositions, Methods of Making, and Uses Thereof |
| CN105555290A (en) * | 2013-05-10 | 2016-05-04 | 莱顿大学学术医院以Lumc的名义运作 | Antimicrobial peptide |
| WO2017197542A1 (en) * | 2016-05-20 | 2017-11-23 | 浙江红雨医药用品有限公司 | Antibacterial dressing, and preparation method and use thereof |
| CN106755229A (en) * | 2016-11-24 | 2017-05-31 | 福州大学 | A kind of preparation method of schizochytrium limacinum algae cake protein Peptides |
Non-Patent Citations (4)
| Title |
|---|
| GEETANJALI MEHER，等: "Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide", 《J. PHYS. CHEM. B》 * |
| 崔春: "《食物蛋白质控制酶解技术》", 30 June 2018, 中国轻工业出版社 * |
| 李青叶: "驴血清蛋白酶解物生产工艺的优化及活性初步研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
| 梁双振: "源于海洋微藻生物活性肽的研究", 《中国优秀博硕士学位论文全文数据库(硕士) 基础科学辑》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111474350A (en) * | 2020-04-23 | 2020-07-31 | 中国林业科学研究院林业研究所 | Kit for detecting coronavirus S1 antigen and non-diagnosis-purpose detection method thereof |
| CN111474350B (en) * | 2020-04-23 | 2023-07-07 | 中国林业科学研究院林业研究所 | Kit for detecting coronavirus S1 antigen and detection method for non-diagnostic purpose thereof |
| WO2022084931A1 (en) * | 2020-10-23 | 2022-04-28 | Antonio Bianchi | Spray formulation for nasal/oral use with activity against respiratory coronaviruses and in particular the sars-cov-2 virus |
| IT202100016037A1 (en) * | 2021-06-18 | 2021-09-18 | Antonio Bianchi | SPRAY FORMULATION FOR NASAL/ORAL USE WITH ACTIVITY AGAINST RESPIRATORY CORONAVIRUSES |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111012736A (en) | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov | |
| Siniavin et al. | Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2 | |
| DK180405B1 (en) | Novel trypsin isoforms and their use | |
| JP2021509809A (en) | Peptides with protease activity for use in the treatment or prevention of coronavirus infections | |
| CN111728963A (en) | Application of copper gluconate in preparing medicine for preventing or treating novel coronavirus infection | |
| US11304989B2 (en) | Peptides for use in the treatment of viral infections | |
| EP4146245A1 (en) | Mannose-binding lectin for treatment or prophylaxis of infectious diseases | |
| Pineda et al. | Quinacrine as a potential treatment for COVID-19 virus infection. | |
| JPH06507386A (en) | therapeutic peptides | |
| WO2021216687A1 (en) | Peptides for the treatment of covid-19 | |
| EP3930730A1 (en) | Method of prophylaxis of coronavirus and/or respiratory syncytial virus infection | |
| EP4147702A1 (en) | Novel combination of heparin and ace2 decoys for the treatment of covid-19 | |
| US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
| US5900401A (en) | Remedy for respiratory-tract viral disease | |
| DK2544705T3 (en) | INTERFERON BETA TO USE IN THE LOWER AIR TRANSMISSION CAUSED BY INFLUENZA | |
| CA2088788C (en) | Peptides that block human immunodeficiency virus infections and methods of use thereof | |
| US20240000901A1 (en) | Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection | |
| Kobayashi-Sakamoto et al. | Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection | |
| Priadharsini et al. | Lung Recruitability in COVID-19 | |
| Quay et al. | AT-H201 constituents collectively are the most potent inhibitors of SARS-CoV-2 infectivity in VERO cells identified and mechanistically act as a chemical vaccine: Human safety data support rapid clinical development as inhaled therapy for COVID-19 | |
| Tavakoli et al. | Oral symptoms of patients tested positive for COVID-19 with mild severity-a cross-sectional study | |
| MXPA96004207A (en) | Novedous remedy for tractor pyrrato viral disease | |
| CN104311644A (en) | Polypeptide, method for improving stability of polypeptide, pharmaceutical composition and application of polypeptide in preparation of medicaments | |
| Bazarova et al. | Clinical and Immunological Considerations of Monoclonal Antibody Therapy in COVID-19: A Review | |
| EP1500662A2 (en) | Stabilizing peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200417 |
|
| WD01 | Invention patent application deemed withdrawn after publication |